Organo Proteins Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
- Paid Up Capital ₹ 6.01 Cr
- Company Age 3 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 11.74 Cr
- Revenue Growth %
- Profit Growth -17.57%
- Ebitda -17.00%
- Net Worth -3.30%
- Total Assets 285.51%
About Organo Proteins
Organo Proteins Private Limited (OPPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 July 2021 (Three years and six months 11 days old ). Its registered office is in Ernakulam, Kerala, India.
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 6.01 Cr.
The company currently has active open charges totaling ₹11.74 Cr.
Thuruvittaseril Joykutty, Abey Mathew, and Jacob Mathew serve as directors at the Company.
Company Details
- Location
Ernakulam, Kerala, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U15100KL2021PTC069920
- Company No.
069920
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Jul 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Organo Proteins?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Thuruvittaseril Joykutty  | Managing Director | 20-Jul-2021 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Abey Mathew | Director | 20-Jul-2021 | Current |
| Jacob Mathew | Director | 20-Jul-2021 | Current |
Financial Performance of Organo Proteins.
Organo Proteins Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 17.57% decrease in profit. The company's net worth dipped by a decrease of 3.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Organo Proteins?
In 2023, Organo Proteins had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
₹11.74 Cr
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 11.74 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Mar 2023 | State Bank Of India | ₹11.74 Cr | Open |
How Many Employees Work at Organo Proteins?
Organo Proteins has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Organo Proteins, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Organo Proteins's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.